Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels

Nicola A. Hanania; Robert F. Lemanske; Phillip E. Korenblat; Joseph R. Arron; Jeffrey M. Harris; Zheng Su; Sofia Mosesova; John G. Matthews; Merdad V. Parsey; Sean P. Bohen

doi:10.1183/13993003/erj.38.suppl_55.3426

Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels

Identifier:nobleid.org/w1/20260515/4EBFFA29

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/4EBFFA29.svg?ark=w1%2F20260515%2F4EBFFA29)](https://nobleid.org/work/w1/20260515/4EBFFA29)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels

Identifier:nobleid.org/w1/20260515/4EBFFA29

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/4EBFFA29.svg?ark=w1%2F20260515%2F4EBFFA29)](https://nobleid.org/work/w1/20260515/4EBFFA29)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work